TY - JOUR
T1 - Cancer stem cells
T2 - The potential of carbon ion beam radiation and new radiosensitizers (Review)
AU - Baek, Sung Jae
AU - Ishii, Hideshi
AU - Tamari, Keisuke
AU - Hayashi, Kazuhiko
AU - Nishida, Naohiro
AU - Konno, Masamitsu
AU - Kawamoto, Koichi
AU - Koseki, Jun
AU - Fukusumi, Takahito
AU - Hasegawa, Shinichiro
AU - Ogawa, Hisataka
AU - Hamabe, Atsushi
AU - Miyo, Masaaki
AU - Noguchi, Kozo
AU - Seo, Yuji
AU - Doki, Yuichiro
AU - Mori, Masaki
AU - Ogawa, Kazuhiko
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Cancer stem cells (CSCs) are a small population of cells in cancer with stem-like properties such as cell proliferation, multiple differentiation and tumor initiation capacities. CSCs are therapy-resistant and cause cancer metastasis and recurrence. One key issue in cancer therapy is how to target and eliminate CSCs, in order to cure cancer completely without relapse and metastasis. To target CSCs, many cell surface markers, DNAs and microRNAs are considered as CSC markers. To date, the majority of the reported markers are not very specific to CSCs and are also present in non- CSCs. However, the combination of several markers is quite valuable for identifying and targeting CSCs, although more specific identification methods are needed. While CSCs are considered as critical therapeutic targets, useful treatment methods remain to be established. Epigenetic gene regulators, microRNAs, are associated with tumor initiation and progression. MicroRNAs have been recently considered as promising therapeutic targets, which can alter the therapeutic resistance of CSCs through epigenetic modification. Moreover, carbon ion beam radiotherapy is a promising treatment for CSCs. Evidence indicates that the carbon ion beam is more effective against CSCs than the conventional X-ray beam. Combination therapies of radiosensitizing microRNAs and carbon ion beam radiotherapy may be a promising cancer strategy. This review focuses on the identification and treatment resistance of CSCs and the potential of microRNAs as new radiosensitizers and carbon ion beam radiotherapy as a promising therapeutic strategy against CSCs.
AB - Cancer stem cells (CSCs) are a small population of cells in cancer with stem-like properties such as cell proliferation, multiple differentiation and tumor initiation capacities. CSCs are therapy-resistant and cause cancer metastasis and recurrence. One key issue in cancer therapy is how to target and eliminate CSCs, in order to cure cancer completely without relapse and metastasis. To target CSCs, many cell surface markers, DNAs and microRNAs are considered as CSC markers. To date, the majority of the reported markers are not very specific to CSCs and are also present in non- CSCs. However, the combination of several markers is quite valuable for identifying and targeting CSCs, although more specific identification methods are needed. While CSCs are considered as critical therapeutic targets, useful treatment methods remain to be established. Epigenetic gene regulators, microRNAs, are associated with tumor initiation and progression. MicroRNAs have been recently considered as promising therapeutic targets, which can alter the therapeutic resistance of CSCs through epigenetic modification. Moreover, carbon ion beam radiotherapy is a promising treatment for CSCs. Evidence indicates that the carbon ion beam is more effective against CSCs than the conventional X-ray beam. Combination therapies of radiosensitizing microRNAs and carbon ion beam radiotherapy may be a promising cancer strategy. This review focuses on the identification and treatment resistance of CSCs and the potential of microRNAs as new radiosensitizers and carbon ion beam radiotherapy as a promising therapeutic strategy against CSCs.
UR - http://www.scopus.com/inward/record.url?scp=84941964765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941964765&partnerID=8YFLogxK
U2 - 10.3892/or.2015.4236
DO - 10.3892/or.2015.4236
M3 - Review article
C2 - 26330103
AN - SCOPUS:84941964765
SN - 1021-335X
VL - 34
SP - 2233
EP - 2237
JO - Oncology Reports
JF - Oncology Reports
IS - 5
ER -